Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amniotic Fluid Stem Cells for Progressive MS
NCT06841068Phase 2Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Feb 2026
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in multiple sclerosis (MS), sponsored by Wake Forest University Health Sciences. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 12 months. Planned start Feb 2026; status: withdrawn.
02
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06841068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06841068.